-The Business Standard CAG says GSPL did not safeguard its own interest leading to passing on of undue benefit of Rs 52 cr to RIL In what could add more teeth to the opposition party's allegations against the Narendra Modi-LED Gujarat government, the Comptroller and Auditor General of India (CAG)'s latest report has brought out fresh details of undue favour by state public sector undertakings (PSUs) to Reliance Industries Limited (RIL) and...
More »SEARCH RESULT
Total Matching Records found : 6375
Glivec lesson for pharma: Patented drugs must be priced smartly-Kiran Mazumdar Shaw
-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...
More »TroubLED by protests, Sterlite awaits green tribunal’s order -Gopu Mohan
-The Indian Express Chennai: The fate of Sterlite Industries, and that of thousands of people of coastal Tuticorin, now depends on the south bench of the National Green Tribunal, which is hearing the company's petition against its closure ordered by the Tamil Nadu Pollution Control Board (TNPCB). The biggest copper smelting unit in the country, part of the Vedanta Group, moved the tribunal after the TNPCB ordered closure of the plant following...
More »Supreme Court's Glivec ruling will ruin innovation
-The Economic Times Extension of life is priceless. Simply priceless." These were the words of Venkat Krishnan (name changed) to Novartis after receiving treatment with Glivec for about two years. Following his diagnosis with chronic myeloid leukaemia (CML), Venkat married his college sweetheart against the wishes of her family. After all, the prognosis in those days for people suffering from CML was not promising. Taking interferon, a powerful immune therapy, was the...
More »SC’s Glivec ruling setback to foreign pharma firms -Vidya Krishnan and CH Unnikrishnan
-Live Mint SC rejects Novartis's patent plea for Glivec, says it does not meet any standard of novelty or inventiveness In a landmark judgement, India's apex court rejected Swiss drug maker Novartis AG's legal challenge aimed at securing a patent for blockbuster anti-cancer drug imatinib mesylate, branded Glivec in the country. The verdict, which is seen as a setback to multinational pharmaceutical companies operating in India, may influence a rash of pending disputes...
More »
